BRIEF published on 08/12/2024 at 13:05, 1 year 9 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 9 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 11 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 11 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 11 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 11 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 11 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 11 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 11 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 11 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 06/11/2026 at 02:45, 13 minutes ago Drilling Completed at High-Grade Tolmer Silver Discovery
Published on 06/11/2026 at 02:35, 23 minutes ago Panther Minerals Announces Appointment of Harrison Glancy to Board of Directors
Published on 06/11/2026 at 02:00, 58 minutes ago Gold Basin Resources Announces Completion of Arrangement with CANEX
Published on 06/11/2026 at 01:55, 1 hour 3 minutes ago Pathfinder Ventures Inc. Provides Update on Revoked Cease Trade Order and Trading Reinstatement Process
Published on 06/10/2026 at 23:56, 3 hours 1 minute ago EQS-Adhoc: HUGO BOSS AG: HUGO BOSS informs about unsolicited voluntary takeover offer by Frasers Group plc
Published on 06/10/2026 at 22:05, 4 hours 52 minutes ago Ridgewood Infrastructure Acquires Dauntless Air, Premier Provider of Emergency Management Infrastructure
Published on 06/10/2026 at 21:45, 5 hours 12 minutes ago EQS-Adhoc: MAHLE has successfully priced the issuance of additional EUR 200 million notes due 2032 and is launching a partial tender offer for its outstanding notes due 2028
Published on 06/10/2026 at 20:11, 6 hours 46 minutes ago EQS-Adhoc: EDAG Engineering Group AG: Board of Directors resolves on capital measures to strengthen capital base
Published on 06/10/2026 at 18:39, 8 hours 18 minutes ago EQS-Adhoc: Kontron AG: Ad hoc announcement / Ennoconn Corporation intends to launch a mandatory takeover offer to Kontron AG shareholders
Published on 06/10/2026 at 18:29, 8 hours 28 minutes ago ICADE – PR – OUTCOME OF THE COMBINED GENERAL MEETING HELD ON JUNE 10 2026
Published on 06/10/2026 at 17:40, 9 hours 18 minutes ago Report on share repurchases from 3 to 9 June 2026
Published on 06/10/2026 at 07:00, 19 hours 58 minutes ago Acceleration of Museum Studio's international expansion
Published on 06/09/2026 at 19:30, 1 day 7 hours ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
